NCT04507724

Brief Summary

Chronic wounds represent a growing challenge in medical care. Part 1: The aim of this part of the study was to collect wound swabs and to answer the question whether the rapid diagnostic tool using enzyme activities can display an infection prematurely. This means that an increased enzyme activity (especially MPO, NHE, LYS, gelatinase, pH) measured overed 3 days, would indicate a change in the wound bed (infection, Inflammation) earlier than the regularly performed clinical assessment. Part 2: The aim of this part of the study was to evaluate (I) the possibility of wound fluid acquisition by means of an "additional collector" during ongoing NPWT and to answer if (II) this secretion can be biochemically analyzed for enzyme activities in order to be able to detect a change in the wound situation at an early stage.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
41

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 19, 2018

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

July 22, 2020

Completed
20 days until next milestone

First Posted

Study publicly available on registry

August 11, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

May 18, 2021

Status Verified

May 1, 2021

Enrollment Period

2.2 years

First QC Date

July 22, 2020

Last Update Submit

May 17, 2021

Conditions

Keywords

wound infectionnegative pressure wound therapydiagnostic toolbiomarker

Outcome Measures

Primary Outcomes (2)

  • Part 1: biochemical analysis of wounds

    Elevated enzyme activities (biochemical analysis of wound swabs) give information of the condition of the wound bed (infection, inflammation).

    during hospitalization

  • Part 2: Descriptive assessment of the feasibility of collecting wound fluid during ongoing negative pressure wound therapy

    The aim is to answer the question if it is feasible to collect wound fluid during ongoing negative pressure wound therapy and analyze this wound fluid biochemically.

    during negative pressure wound therapy

Secondary Outcomes (1)

  • Part 2: Evaluating changes in enzyme activities in the collected wound fluid

    Starting immediately after installation of the negative-pressure dressing and lasting for 3 days.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The cohort will be selected by inpatients with wounds (part 1) or with negative pressure wound therapy (part 2)

You may qualify if:

  • signed informed consent
  • older than 18 years old
  • open wound of varying etiology
  • VAC therapy (KCI) (part 2)

You may not qualify if:

  • under 18 years old
  • pregnant women
  • less than three measurement data (less than three swabs) = part 1
  • VAC-instill therapy = part 2

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery, Medical University of Graz

Graz, 8010, Austria

Location

Related Publications (23)

  • McDaniel JC, Roy S, Wilgus TA. Neutrophil activity in chronic venous leg ulcers--a target for therapy? Wound Repair Regen. 2013 May-Jun;21(3):339-51. doi: 10.1111/wrr.12036. Epub 2013 Mar 28.

    PMID: 23551462BACKGROUND
  • Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen. 2000 Jan-Feb;8(1):13-25. doi: 10.1046/j.1524-475x.2000.00013.x.

    PMID: 10760211BACKGROUND
  • Ladwig GP, Robson MC, Liu R, Kuhn MA, Muir DF, Schultz GS. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen. 2002 Jan-Feb;10(1):26-37. doi: 10.1046/j.1524-475x.2002.10903.x.

    PMID: 11983004BACKGROUND
  • Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol. 1996 Nov;107(5):743-8. doi: 10.1111/1523-1747.ep12365637.

    PMID: 8875960BACKGROUND
  • Izadi K, Ganchi P. Chronic wounds. Clin Plast Surg. 2005 Apr;32(2):209-22. doi: 10.1016/j.cps.2004.11.011.

    PMID: 15814118BACKGROUND
  • Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience. Ann Plast Surg. 1997 Jun;38(6):563-76; discussion 577.

    PMID: 9188971BACKGROUND
  • James GA, Swogger E, Wolcott R, Pulcini Ed, Secor P, Sestrich J, Costerton JW, Stewart PS. Biofilms in chronic wounds. Wound Repair Regen. 2008 Jan-Feb;16(1):37-44. doi: 10.1111/j.1524-475X.2007.00321.x. Epub 2007 Dec 13.

    PMID: 18086294BACKGROUND
  • Steenvoorde P, van Engeland A, Oskam J. Vacuum-assisted closure therapy and oral anticoagulation therapy. Plast Reconstr Surg. 2004 Jun;113(7):2220-1. doi: 10.1097/01.prs.0000123603.32963.11. No abstract available.

    PMID: 15253223BACKGROUND
  • Morykwas MJ, Argenta LC, Shelton-Brown EI, McGuirt W. Vacuum-assisted closure: a new method for wound control and treatment: animal studies and basic foundation. Ann Plast Surg. 1997 Jun;38(6):553-62. doi: 10.1097/00000637-199706000-00001.

    PMID: 9188970BACKGROUND
  • Huang C, Leavitt T, Bayer LR, Orgill DP. Effect of negative pressure wound therapy on wound healing. Curr Probl Surg. 2014 Jul;51(7):301-31. doi: 10.1067/j.cpsurg.2014.04.001. Epub 2014 Apr 26.

    PMID: 24935079BACKGROUND
  • Nuutila K, Yang L, Broomhead M, Proppe K, Eriksson E. Novel negative pressure wound therapy device without foam or gauze is effective at -50 mmHg. Wound Repair Regen. 2019 Mar;27(2):162-169. doi: 10.1111/wrr.3. Epub 2018 Oct 31.

    PMID: 30378215BACKGROUND
  • Isago T, Nozaki M, Kikuchi Y, Honda T, Nakazawa H. Effects of different negative pressures on reduction of wounds in negative pressure dressings. J Dermatol. 2003 Aug;30(8):596-601. doi: 10.1111/j.1346-8138.2003.tb00441.x.

    PMID: 12928528BACKGROUND
  • Fleischmann W, Russ M, Westhauser A, Stampehl M. [Vacuum sealing as carrier system for controlled local drug administration in wound infection]. Unfallchirurg. 1998 Aug;101(8):649-54. doi: 10.1007/s001130050318. German.

    PMID: 9782769BACKGROUND
  • Timmers MS, Graafland N, Bernards AT, Nelissen RG, van Dissel JT, Jukema GN. Negative pressure wound treatment with polyvinyl alcohol foam and polyhexanide antiseptic solution instillation in posttraumatic osteomyelitis. Wound Repair Regen. 2009 Mar-Apr;17(2):278-86. doi: 10.1111/j.1524-475X.2009.00458.x.

    PMID: 19320897BACKGROUND
  • Blokhuis-Arkes MH, Haalboom M, van der Palen J, Heinzle A, Sigl E, Guebitz G, Beuk R. Rapid enzyme analysis as a diagnostic tool for wound infection: Comparison between clinical judgment, microbiological analysis, and enzyme analysis. Wound Repair Regen. 2015 May-Jun;23(3):345-52. doi: 10.1111/wrr.12282. Epub 2015 Jun 19.

    PMID: 25816836BACKGROUND
  • Hasmann A, Wehrschuetz-Sigl E, Marold A, Wiesbauer H, Schoeftner R, Gewessler U, Kandelbauer A, Schiffer D, Schneider KP, Binder B, Schintler M, Guebitz GM. Analysis of myeloperoxidase activity in wound fluids as a marker of infection. Ann Clin Biochem. 2013 May;50(Pt 3):245-54. doi: 10.1258/acb.2011.010249.

    PMID: 23404930BACKGROUND
  • Hasmann A, Gewessler U, Hulla E, Schneider KP, Binder B, Francesko A, Tzanov T, Schintler M, Van der Palen J, Guebitz GM, Wehrschuetz-Sigl E. Sensor materials for the detection of human neutrophil elastase and cathepsin G activity in wound fluid. Exp Dermatol. 2011 Jun;20(6):508-13. doi: 10.1111/j.1600-0625.2011.01256.x. Epub 2011 Apr 13.

    PMID: 21488974BACKGROUND
  • Hasmann A, Wehrschuetz-Sigl E, Kanzler G, Gewessler U, Hulla E, Schneider KP, Binder B, Schintler M, Guebitz GM. Novel peptidoglycan-based diagnostic devices for detection of wound infection. Diagn Microbiol Infect Dis. 2011 Sep;71(1):12-23. doi: 10.1016/j.diagmicrobio.2010.09.009. Epub 2011 Mar 9.

    PMID: 21388768BACKGROUND
  • Klebanoff SJ. Myeloperoxidase. Proc Assoc Am Physicians. 1999 Sep-Oct;111(5):383-9. doi: 10.1111/paa.1999.111.5.383.

    PMID: 10519157BACKGROUND
  • Schiffer D, Blokhuis-Arkes M, van der Palen J, Sigl E, Heinzle A, Guebitz GM. Assessment of infection in chronic wounds based on the activities of elastase, lysozyme and myeloperoxidase. Br J Dermatol. 2015 Dec;173(6):1529-31. doi: 10.1111/bjd.13896. Epub 2015 Oct 29. No abstract available.

    PMID: 25965963BACKGROUND
  • Heinzle A, Papen-Botterhuis NE, Schiffer D, Schneider KP, Binder B, Schintler M, Haaksman IK, Lenting HB, Gubitz GM, Sigl E. Novel protease-based diagnostic devices for detection of wound infection. Wound Repair Regen. 2013 May-Jun;21(3):482-9. doi: 10.1111/wrr.12040. Epub 2013 Apr 29.

    PMID: 23627267BACKGROUND
  • Schiffer D, Tegl G, Heinzle A, Sigl E, Metcalf D, Bowler P, Burnet M, Guebitz GM. Enzyme-responsive polymers for microbial infection detection. Expert Rev Mol Diagn. 2015;15(9):1125-31. doi: 10.1586/14737159.2015.1061935. Epub 2015 Jul 16.

    PMID: 26184576BACKGROUND
  • Tegl G, Schiffer D, Sigl E, Heinzle A, Guebitz GM. Biomarkers for infection: enzymes, microbes, and metabolites. Appl Microbiol Biotechnol. 2015 Jun;99(11):4595-614. doi: 10.1007/s00253-015-6637-7. Epub 2015 May 9.

    PMID: 25952112BACKGROUND

MeSH Terms

Conditions

Wounds and InjuriesWound Infection

Condition Hierarchy (Ancestors)

Infections

Study Officials

  • Michael Schintler, Prof.

    Medical University of Graz

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Sub-Investigator

Study Record Dates

First Submitted

July 22, 2020

First Posted

August 11, 2020

Study Start

October 19, 2018

Primary Completion

December 31, 2020

Study Completion

December 31, 2020

Last Updated

May 18, 2021

Record last verified: 2021-05

Data Sharing

IPD Sharing
Will not share

There is not a plan to make IPD available.

Locations